Evolent Health, Inc.
NYSE:EVHMedical - Healthcare Information Services
-$0.28 today
- Market cap
- $442.05M
- Beta
- 0.83
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.44
Volume 3.10M
Average 2.78M
EVH Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Evolent Health, Inc.NYSE: EVH
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit declines year over year
Q1 FY2026 gross profit of $61.92M fell 39.6% year over year, behind the -27.0% change in trailing-twelve-month gross profit. Sequentially, it rose 18.6% from the prior quarter. Over 3 fiscal years it compounded at -3.6% a year.
Context
- Gross profit amounted to 15.1% of revenue in FY2025, up 0.8 pp from a year earlier.
- Gross profit increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -39.6% toward the trailing-twelve-month pace of -27.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 284.03M USD
- Year-over-year change
- -22.7%
- 4-year CAGR
- +3.2%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 284.03M | -22.7% |
| FY2024 | 2024-12-31 | 367.35M | -20.2% |
| FY2023 | 2023-12-31 | 460.47M | +45.4% |
| FY2022 | 2022-12-31 | 316.58M | +26.4% |
| FY2021 | 2021-12-31 | 250.41M | — |
Gross Profit vs competitors
How EVH compares with its peers on the latest reported figures
- EVH's LTM Mar 2026 gross profit of $266.94M is the 4th highest of the 11 companies compared; the peer median is $70.45M.
- Its year-over-year change of -27.0% is the 8th highest of 9, against a peer median of +2.3%.
- Gross profit amounts to 14.1% of revenue for EVH, versus a peer median of 57.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $944.77M | +15.7% | -23.3% | 27.6% | |
| LTM Mar 2026 | $580M | -0.3% | +6.6% | 70.0% | |
| LTM Mar 2026 | $417.67M | +37.2% | +206.6% | 47.5% | |
| LTM Mar 2026 | $266.94M | -27.0% | -3.6% | 14.1% | |
| LTM Mar 2026 | $202.3M | +4.5% | +3.9% | 64.9% | |
| LTM Mar 2026 | $73.09M | +682.6% | +68.8% | 91.6% | |
| LTM Mar 2026 | $67.81M | +0.0% | — | 94.7% | |
| LTM Mar 2026 | $50.64M | -2.5% | +5.0% | 49.2% | |
| LTM Mar 2026 | $8.85M | -69.0% | — | 13.7% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Dec 2025 | -$848K | — | — | — | |
| Peer median (excluding EVH) | $70.45M | +2.3% | +5.8% | 57.0% | |
Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 907.96M | 1.35B | 1.96B | 2.55B | 1.88B |
| Cost of Revenue | 657.55M | 1.04B | 1.5B | 2.19B | 1.59B |
| Gross Profit | 250.41M | 316.58M | 460.47M | 367.35M | 284.03M |
| Gross Margin | 27.6% | 23.4% | 23.4% | 14.4% | 15.1% |
| Research & Development | 0 | 27M | 0 | 0 | 0 |
| Selling, General & Admin | 219.5M | 269.27M | 358.11M | 263.05M | 288.47M |
| Operating Expenses | 292.82M | 312.94M | 531.68M | 407.84M | 288.47M |
| Depreciation & Amortization | 60.04M | 90.25M | 123.42M | 123.17M | 115.85M |
| EBITDA | 55.66M | 43.75M | (24.79M) | 84.85M | (361.31M) |
| EBITDA Margin | 6.1% | 3.2% | -1.3% | 3.3% | -19.3% |
| Operating Income | (42.41M) | 3.64M | (71.21M) | (40.49M) | (4.44M) |
| Operating Margin | -4.7% | 0.3% | -3.6% | -1.6% | -0.2% |
| Interest Income | 407K | 1.37M | 5.26M | 5.54M | 4.19M |
| Interest Expense | 25.43M | 15.57M | 54.21M | 24.72M | 57.47M |
| Other Income / Expenses | 12.61M | (65.72M) | (131.19M) | (22.55M) | (530.2M) |
| Income Before Tax | (29.8M) | (62.08M) | (202.41M) | (63.04M) | (534.64M) |
| Pre-Tax Margin | -3.3% | -4.6% | -10.3% | -2.5% | -28.5% |
| Income Tax Expense | 483K | (43.38M) | (89.37M) | (1.41M) | (126K) |
| Net Income | (37.6M) | (19.16M) | (113.04M) | (61.62M) | (534.51M) |
| Net Margin | -4.1% | -1.4% | -5.8% | -2.4% | -28.5% |
| EPS (Basic) | (0.36) | (0.20) | (1.28) | (0.81) | (5.07) |
| EPS (Diluted) | (0.36) | (0.20) | (1.28) | (0.81) | (5.07) |
| Weighted Avg Shares | 86.07M | 93.7M | 111.25M | 114.68M | 114.21M |
| Weighted Avg Shares (Diluted) | 86.07M | 93.7M | 111.25M | 114.68M | 114.21M |
Evolent Health, Inc.
NYSE:EVH
Intrinsic Alpha fair value
Locked
Current Price
$3.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.